Susquehanna International Group’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$736K Buy
22,500
+600
+3% +$19.3K ﹤0.01% 8981
2026
Q1
$713K Sell
21,900
-23,800
-52% -$781K ﹤0.01% 8772
2025
Q4
$1.45M Buy
+45,700
New +$1.37M ﹤0.01% 6333
2024
Q2
– Sell
-10,100
Closed -$136K – 13195
2024
Q1
$136K Buy
+10,100
New +$61.2K ﹤0.01% 10981
2021
Q3
– Sell
-37,300
Closed -$1.26M – 13532
2021
Q2
$1.26M Buy
37,300
+19,900
+114% +$703K ﹤0.01% 7120
2021
Q1
$676K Buy
17,400
+3,400
+24% +$194K ﹤0.01% 8759
2020
Q4
$867K Buy
14,000
+1,700
+14% +$77.9K ﹤0.01% 7048
2020
Q3
$412K Sell
12,300
-2,000
-14% -$57.1K ﹤0.01% 8080
2020
Q2
$341K Buy
+14,300
New +$339K ﹤0.01% 8130

Other funds holding STOK

Susquehanna International Group's STOK Position: Q2 2026 in Review

Susquehanna International Group sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 57,291 shares — an estimated $1.84M sold.

Susquehanna International Group first reported a position in STOK in Q1 2020 and held it in 21 quarters. The position peaked at $2.07M in Q4 2024. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Susquehanna International Group reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Susquehanna International Group sold 57,291 Stoke Therapeutics shares in Q2 2026, an estimated $1.84M.
  • Susquehanna International Group first reported a position in Stoke Therapeutics in Q1 2020 and held it in 21 quarters.
  • Susquehanna International Group's Stoke Therapeutics position peaked at $2.07M in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.